Role of TGF-β signaling in EMT, cancer progression and metastasis

Drug Discovery Today: Disease Models

Volumn 8, Issue 2-3, 2011, Pages 121-126

  Savary, Katia ^a   Moustakas, Aristidis ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 82455199152     PISSN: None     EISSN: 17406757     Source Type: Journal    
DOI: 10.1016/j.ddmod.2011.07.009     Document Type: Review

References (52)

1. Bierie, B. and Moses, H. L. (2006) Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506-520 (Pubitemid 43980540)
2. Massagué, J. (2008) TGFβ in cancer. Cell 134, 215-230
3. Kang, J. S. et al. (2009) New regulatory mechanisms of TGF-β receptor function. Trends Cell Biol. 19, 385-394
4. Daly, A. C. et al. (2010) Smad3 protein levels are modulated by Ras activity and during the cell cycle to dictate transforming growth factor-β responses. J. Biol. Chem. 285, 6489-6497
5. Erickson, R. A. and Liu, X. (2009) Association of v-ErbA with Smad4 disrupts TGF-β signaling. Mol. Biol. Cell 20, 1509-1519
6. Singh, G. et al. (2010) Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-β switch from a suppressor to a promoter of cancer cell proliferation. J. Biol. Chem. 285, 27241-27250
7. Thiery, J. P. et al. (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890
8. Huber, M. A. et al. (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17, 548-558 (Pubitemid 41267170)
9. Valcourt, U. et al. (2005) TGF-β and the Smad signaling pathway support transcriptomic reprogramming during epithelial mesenchymal cell transition. Mol. Biol. Cell 16, 1987-2002 (Pubitemid 40471965)
10. Gal, A. et al. (2008) Sustained TGFβ exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 27, 1218-1230 (Pubitemid 351294691)
11. Brown, K. A. et al. (2004) Induction by transforming growth factor-β1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res. 6, R215-R231
12. Gotzmann, J. et al. (2006) A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes. Oncogene 25, 3170-3185 (Pubitemid 43881558)
13. Shirakihara, T. et al. (2011) TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 30, 783-795
14. Waerner, T. et al. (2006) ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell 10, 227-239 (Pubitemid 44311068)
15. Chaudhury, A. et al. (2010) TGF-β-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat. Cell Biol. 12, 286-293
16. Ju, W. et al. (2006) Deletion of Smad2 in mouse liver reveals novel functionsinhepatocytegrowthand differentiation. Mol. Cell Biol. 26, 654-667 (Pubitemid 43089776)
17. Hoot, K. E. et al. (2008) Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J. Clin. Invest. 118, 2722-2732
18. Petersen, M. et al. (2010) Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene 29, 1351-1361
19. Eckert, M. A. et al. (2011) Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 19, 372-386
20. Thuault, S. et al. (2008) TGF-β and Smad signaling in transcriptome reprogramming during EMT. In Transforming Growth Factor-β in Cancer Therapy. Basic and Clinical Biology, (Vol. I) (Jakowlew, S. B., ed.), pp. 259-273, The Human Press Inc
21. Brandl, M. et al. (2010) IKKα controls canonical TGFβ-SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in panc1 cells. J. Cell Sci. 123 (Pt 24), 4231-4239
22. Smith, A. P. et al. (2009) A positive role for Myc in TGFβ-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 28, 422-430
23. Horiguchi, K. et al. (2009) Role of Ras signaling in the induction of snail by transforming growth factor-β. J. Biol. Chem. 284, 245-253
24. Peinado, H. et al. (2003) Transforming growth factor β-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem. 278, 21113-21123 (Pubitemid 36806424)
25. Alcorn, J. F. et al. (2008) Jun. N-terminal kinase 1 regulates epithelial-epithelial-to-mesenchymaltransition induced by TGF-β1. J. CellSci. 121 (Pt7), 1036-1045 (Pubitemid 351639422)
26. Vincent, T. et al. (2009) A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial-mesenchymal transition. Nat. Cell Biol. 11, 943-950
27. Burk, U. et al. (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582-589 (Pubitemid 351772923)
28. Gregory, P. A. et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (Pubitemid 351627379)
29. Gregory, P. A. et al. (2011) An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol. Biol. Cell 22, 1686-1698
30. Adorno, M. et al. (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 137, 87-98
31. Papageorgis, P. et al. (2010) Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res. 70, 968-978
32. Giampieri, S. et al. (2009) Localized and reversible TGFb signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 11, 1287-1296
33. Korpal, M. et al. (2009) Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960-966
34. Tsushima, H. et al. (1996) High levels of transforming growth factor β 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 110, 375-382 (Pubitemid 26043869)
35. Micalizzi, D. S. et al. (2009) The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling. J. Clin. Invest. 119, 2678-2690
36. Viloria-Petit, A. M. et al. (2009) A role for the TGFβ-Par6 polarity pathway in breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 106, 14028-14033
37. Mani, S. A. et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (Pubitemid 351636299)
38. McCoy, E. L. et al. (2009) Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J. Clin. Invest. 119, 2663-2677
39. Shipitsin, M. et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273 (Pubitemid 46349843)
40. Padua, D. et al. (2008) TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77 (Pubitemid 351442989)
41. Hannigan, A. et al. (2010) Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter. J. Clin. Invest. 120, 2842-2857
42. Weeks, B. H. et al. (2001) Inducible expression of transforming growth factor β1 in papillomas causes rapid metastasis. Cancer Res 61, 7435-7443 (Pubitemid 32995031)
43. Bierie, B. et al. (2009) Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 119, 1571-1582
44. Nam, J. S. et al. (2008) An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835-3843
45. Yang, L. et al. (2008) Abrogation of TGF β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23-35 (Pubitemid 350309741)
46. Mohammad, K. S. et al. (2011) TGF-β-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 71, 175-184
47. Biswas, S. et al. (2007) Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117, 1305-1313 (Pubitemid 46718418)
48. Melisi, D. et al. (2008) LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7, 829-840 (Pubitemid 351551036)
49. Yang, Y. A. et al. (2002) Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615
50. Guasch, G. et al. (2007) Loss of TGFβ signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12, 313-327 (Pubitemid 47539305)
51. Ijichi, H. et al. (2006) Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor- β signaling in cooperation with active Kras expression. Genes Dev. 20, 3147-3160 (Pubitemid 44790629)
52. Lu, S. L. et al. (2006) Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 20, 1331-1342